Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349983 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)
A Phase 1 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03349983 is a Phase 1 study that has completed, run by Bavarian Nordic. The registered enrollment target is 11 participants.
The verdict
NCT03349983, a Phase 1 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
An open-label Phase 1 trial to evaluate the safety and tolerability of MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines modified to express brachyury and T-cell costimulatory molecules in patients with a metastatic or unresectable locally advanced malignant solid tumor. Subjects will be given the following subcutaneous doses: two prime doses with MVA-BN-Brachyury and monthly boost doses with FPV-Brachyury for 6 months. The study will last approximately 104 weeks before starting long term follow up (FU).
Interventions
- BIOLOGICAL MVA-BN-Brachyury/ FPV-Brachyury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-01-08 |
| Est. Completion | 2020-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03349983
The ClinicalTrials.gov registry entry for NCT03349983 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA-BN-Brachyury/ FPV-Brachyury is the first listed.
NCT03349983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03349983 about?
NCT03349983 is a clinical study titled "Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)". An open-label Phase 1 trial to evaluate the safety and tolerability of MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines modified to express brachyury and T-cell costimulatory molecules in patients with a metastatic or unresectable locally advanced malignant solid tumor. Subjects will be giv...
What is the current status of trial NCT03349983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2018-01-08. Estimated completion is 2020-06-13.
What interventions are being tested in trial NCT03349983?
The interventions under investigation include: MVA-BN-Brachyury/ FPV-Brachyury (BIOLOGICAL).
Who is sponsoring clinical trial NCT03349983?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.